Korea’s leading drugmakers hit by sluggish sales

Published: 2010-06-29 06:59:00

Updated: 2010-06-29 06:59:00

Influenced by anti-rebate sales policies, domestic leading pharmaceutical firms, Dong-A Pharm, Hanmi Pharm, Daewoong Pharm and Yuhan Corp., saw their monthly sales plunge, according to pharmaceutical business sources.

So far, large pharmaceutical companies have endeavored to refrain from using...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK